{"generic":"Pentosan Polysulfate Sodium","drugs":["Elmiron","Pentosan Polysulfate Sodium"],"mono":{"0":{"id":"jsoss0","title":"Generic Names","mono":"Pentosan Polysulfate Sodium"},"1":{"id":"jsoss1","title":"Dosing and Indications","sub":{"0":{"id":"jsoss1b4","title":"Adult Dosing","mono":"<b>Interstitial cystitis, chronic, relief of bladder pain or discomfort:<\/b> 100 mg ORALLY three times a day taken either 1 hour before or 2 hours after meals "},"1":{"id":"jsoss1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy in pediatric patients below the age of 16 years have not been established<\/li><li><b>Interstitial cystitis, chronic, relief of bladder pain or discomfort:<\/b> 16 years and older, 100 mg ORALLY three times a day taken either 1 hour before or 2 hours after meals<\/li><\/ul>"},"3":{"id":"jsoss1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Interstitial cystitis, chronic, relief of bladder pain or discomfort<br\/>"}}},"3":{"id":"jsoss3","title":"Contraindications\/Warnings","sub":[{"id":"jsoss3b9","title":"Contraindications","mono":"hypersensitivity to pentosan polysulfate sodium, any related compound, or any component of the product <br\/>"},{"id":"jsoss3b10","title":"Precautions","mono":"<ul><li>alopecia, typically limited to a single area on the scalp, may occur<\/li><li>aneurysms; may increase risk of hemorrhage<\/li><li>bleeding disorders, invasive procedures, concomitant anticoagulant therapy; may increase risk of hemorrhage<\/li><li>gastrointestinal ulceration, diverticula, or polyps; may increase risk of hemorrhage<\/li><li>hemophilia; may increase risk of hemorrhage<\/li><li>heparin-induced thrombocytopenia, history of<\/li><li>hepatic insufficiency; potential toxicity<\/li><li>splenic disorders; potential toxicity<\/li><\/ul>"},{"id":"jsoss3b11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"jsoss3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jsoss4","title":"Drug Interactions","sub":{"1":{"id":"jsoss4b14","title":"Major","mono":"<ul><li>Aceclofenac (theoretical)<\/li><li>Acemetacin (theoretical)<\/li><li>Acenocoumarol (theoretical)<\/li><li>Alteplase, Recombinant (theoretical)<\/li><li>Amtolmetin Guacil (theoretical)<\/li><li>Anistreplase (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Bromfenac (theoretical)<\/li><li>Bufexamac (theoretical)<\/li><li>Celecoxib (theoretical)<\/li><li>Chamomile (theoretical)<\/li><li>Choline Salicylate (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clonixin (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dexibuprofen (theoretical)<\/li><li>Dexketoprofen (theoretical)<\/li><li>Diclofenac (theoretical)<\/li><li>Diflunisal (theoretical)<\/li><li>Dipyrone (theoretical)<\/li><li>Drotrecogin Alfa (theoretical)<\/li><li>Enoxaparin (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Etodolac (theoretical)<\/li><li>Etofenamate (theoretical)<\/li><li>Etoricoxib (theoretical)<\/li><li>Felbinac (theoretical)<\/li><li>Fenoprofen (theoretical)<\/li><li>Fepradinol (theoretical)<\/li><li>Feprazone (theoretical)<\/li><li>Floctafenine (theoretical)<\/li><li>Flufenamic Acid (theoretical)<\/li><li>Fluoxetine (probable)<\/li><li>Flurbiprofen (theoretical)<\/li><li>Fluvoxamine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Garlic (probable)<\/li><li>Heparin (theoretical)<\/li><li>Ibuprofen (theoretical)<\/li><li>Ibuprofen Lysine (theoretical)<\/li><li>Indomethacin (theoretical)<\/li><li>Ketoprofen (theoretical)<\/li><li>Ketorolac (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Lornoxicam (theoretical)<\/li><li>Loxoprofen (theoretical)<\/li><li>Lumiracoxib (theoretical)<\/li><li>Meclofenamate (theoretical)<\/li><li>Mefenamic Acid (theoretical)<\/li><li>Meloxicam (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Morniflumate (theoretical)<\/li><li>Nabumetone (theoretical)<\/li><li>Naproxen (theoretical)<\/li><li>Nepafenac (theoretical)<\/li><li>Niflumic Acid (theoretical)<\/li><li>Nimesulide (theoretical)<\/li><li>Oxaprozin (theoretical)<\/li><li>Oxyphenbutazone (theoretical)<\/li><li>Papaya (theoretical)<\/li><li>Parecoxib (theoretical)<\/li><li>Paroxetine (probable)<\/li><li>Phenindione (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Phenylbutazone (theoretical)<\/li><li>Piketoprofen (theoretical)<\/li><li>Piroxicam (theoretical)<\/li><li>Proglumetacin (theoretical)<\/li><li>Propionic Acid (theoretical)<\/li><li>Propyphenazone (theoretical)<\/li><li>Proquazone (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reteplase, Recombinant (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Rofecoxib (theoretical)<\/li><li>Salicylic Acid (theoretical)<\/li><li>Salsalate (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Sodium Salicylate (theoretical)<\/li><li>St John's Wort (probable)<\/li><li>Streptokinase (theoretical)<\/li><li>Sulindac (theoretical)<\/li><li>Tan-Shen (probable)<\/li><li>Tenecteplase (theoretical)<\/li><li>Tenoxicam (theoretical)<\/li><li>Tiaprofenic Acid (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Tolfenamic Acid (theoretical)<\/li><li>Tolmetin (theoretical)<\/li><li>Urokinase (theoretical)<\/li><li>Valdecoxib (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"},"2":{"id":"jsoss4b15","title":"Moderate","mono":"<ul><li>Avocado (probable)<\/li><li>Chondroitin (probable)<\/li><li>Coenzyme Q10 (probable)<\/li><li>Curcumin (probable)<\/li><li>Dong Quai (probable)<\/li><li>Ginger (probable)<\/li><li>Vitamin A (probable)<\/li><\/ul>"}}},"5":{"id":"jsoss5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (4%), Rash (0% to 3%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (2%), Diarrhea (2.3% to 4%), Indigestion (up to 2%), Nausea (2.3% to 4%)<\/li><li><b>Hepatic:<\/b>Increased liver enzymes (up to 1.2%)<\/li><li><b>Neurologic:<\/b>Dizziness (1%), Headache (up to 3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Proctitis, Rectal hemorrhage (6.3%)<\/li><li><b>Hematologic:<\/b>Thrombocytopenia (less than or equal to 1%)<\/li><\/ul>"},"6":{"id":"jsoss6","title":"Drug Name Info","sub":{"0":{"id":"jsoss6b17","title":"US Trade Names","mono":"Elmiron<br\/>"},"2":{"id":"jsoss6b19","title":"Class","mono":"Cystitis Agent<br\/>"},"3":{"id":"jsoss6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jsoss6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jsoss7","title":"Mechanism Of Action","mono":"Pentosan polysulfate sodium has anticoagulant and fibrinolytic effects. While the exact mechanism is unknown, it has been found to adhere to the mucosal membrane of the bladder wall and may act as a buffer to control cell permeability which prevents irritating solutes in urine from reaching the cells.<br\/>"},"8":{"id":"jsoss8","title":"Pharmacokinetics","sub":[{"id":"jsoss8b23","title":"Absorption","mono":"<ul><li>Bioavailability: (Oral, capsule), 6%<\/li><li>Effect of food: (Oral), unknown<\/li><\/ul>"},{"id":"jsoss8b24","title":"Distribution","mono":"Genitourinary tract uroepithelium <br\/>"},{"id":"jsoss8b25","title":"Metabolism","mono":"<ul><li>Hepatic; (primary) desulfation<\/li><li>Spleen; (primary) desulfation<\/li><li>Kidney; (secondary) depolymerization<\/li><\/ul>"},{"id":"jsoss8b26","title":"Excretion","mono":"<ul><li>Fecal: (Oral, 300 mg), 84% unchanged<\/li><li>Fecal: (Oral, 450 mg), 58% unchanged<\/li><li>Renal: (Oral), 6%, 0.14% unchanged<\/li><\/ul>"},{"id":"jsoss8b27","title":"Elimination Half Life","mono":"Healthy subjects: (Oral, solution), 20 to 27 hours <br\/>"}]},"9":{"id":"jsoss9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with water at least 1 hour before or 2 hours after meals <br\/>"},"10":{"id":"jsoss10","title":"Monitoring","mono":"<ul><li>reduction in bladder pain or discomfort may indicate efficacy<\/li><li>pain improvement: after 3 months, again in 3 months (if no improvement and no serious adverse effects)<\/li><li>hemorrhage; in patients undergoing invasive procedures, in patients with known or suspected underlying coagulopathy, or at increased risk for bleeding<\/li><\/ul>"},"11":{"id":"jsoss11","title":"How Supplied","mono":"<b>Elmiron<\/b><br\/>Oral Capsule: 100 MG<br\/>"},"13":{"id":"jsoss13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to take drug with water at least 1 h before or 2 h after meals.<\/li><li>Patient should avoid using concurrent aspirin or aspirin-containing products, unless approved by healthcare professional, as this drug may increase the risk of bleeding.<\/li><\/ul>"}}}